LYKA LABS
|
|
| BOM : 500259 NSE : LYKALABS | |
| LT :
Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Jun 20,2025 |
|
Price(EOD): ₹ 113.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 405.91 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LYKA LABS | NA | -4.1% | 3.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | -3.3% | 8.3% |
| DIVIS LABORATORIES | -1.5% | 0.8% | 42.3% |
| CIPLA | -1.7% | 2.3% | -5.8% |
| TORRENT PHARMACEUTICALS | -3.3% | -1.4% | 9.8% |
| DR REDDYS LABORATORIES | -1.6% | 8.4% | 10.6% |
| MANKIND PHARMA | -3.3% | -6.1% | 3.4% |
| ZYDUS LIFESCIENCES | -1.8% | 5.9% | -12% |
| LUPIN | -3.2% | -1.1% | 22.1% |
FUNDAMENTAL ANALYSIS OF LYKA LABS
[ Q(TTM): Mar2025, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LYKA LABS
[As on : Jun 20,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
51.13
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 7.94 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] 3.92
P/B Calculated based on Book Value of Rs 103.55 Cr
[Latest Year - Mar2025 - Consolidated Results ] 2.93
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 138.50 Cr
[Latest Qtr - Mar2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
269% 8% 83% |
SHARE PRICE MOMENTUM OF LYKA LABS
LYKA LABS vs SENSEX
DEBT OF LYKA LABS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0.63 1.21 2.9 1.58 |
0.96 2.58 9.76 4.43 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF LYKA LABS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF LYKA LABS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.09% -21.37% -15.51% -24.95% |
20.39% 101.28% 285.33% 197.22% |
| QtrlyTrend |
0 | |
| Latest Qtr: Mar2025 | ||
| Quarterly Result Analysis → | ||
LYKA LABS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about LYKA LABS
Is LYKA LABS good for long term investment?
As on Jun 20,2025, the Fundamentals of LYKA LABS look Poor and hence it may not be good for long term investment ! See Financial Performance of LYKA LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LYKA LABS UnderValued or OverValued?
As on Jun 20,2025, LYKA LABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of LYKA LABS ?
As on Jun 20,2025, the Intrinsic Value of LYKA LABS is Rs. 62.10 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 30.81
Fair Value [Median EV / Sales Model] : Rs. 105.57
Fair Value [Median Price / Sales Model] : Rs. 62.10
Estimated Median Fair Value of LYKA LABS : Rs. 62.10
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
